BD Exits Glucose Monitoring Market After Being “Eclipsed” By Competitors
This article was originally published in The Gray Sheet
Executive Summary
Becton Dickinson is dropping out of the increasingly competitive blood glucose monitoring market, acknowledging that it has been too slow to innovate in a sector that generated about $105 mil. in BD sales for the 12 months ended Sept. 30
You may also be interested in...
Abbott glucose meter patent suit
San Francisco federal jury rules Aug. 8 that Abbott patent '890 related to blood glucose monitors and test strips is invalid. Abbott had asserted in 2004 that Becton Dickinson and Nova Biomedical, which manufactured certain BD products including the BD Logic monitor, infringed four of its patents. The latest ruling relieves BD/Nova from the last of the four claims. A judge ruled in April that two of the other patents had not been infringed and one was invalid. Abbott had sought $42 million in damages. BD exited the glucose monitoring market in 2006 (1"The Gray Sheet" Oct. 2, 2006, p. 13)
Abbott glucose meter patent suit
San Francisco federal jury rules Aug. 8 that Abbott patent '890 related to blood glucose monitors and test strips is invalid. Abbott had asserted in 2004 that Becton Dickinson and Nova Biomedical, which manufactured certain BD products including the BD Logic monitor, infringed four of its patents. The latest ruling relieves BD/Nova from the last of the four claims. A judge ruled in April that two of the other patents had not been infringed and one was invalid. Abbott had sought $42 million in damages. BD exited the glucose monitoring market in 2006 (1"The Gray Sheet" Oct. 2, 2006, p. 13)
Medtronic Prestige Cervical Disc Rollout Marks 800 Surgeons Trained To Date
Medtronic has trained over 800 surgeons to date on the use of its Prestige artificial cervical disc and will train 200 more each weekend "for the next several weeks," the firm reported Aug. 21 during its fiscal 2008 first quarter earnings call